Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets
[1] [3] Key risk factors for developing hypotension on GLP-1 therapy include: Concurrent use of antihypertensive medications, especially diuretics, ACE inhibitors, or ARBs Concomitant use of SGLT2 inhibitors, which can cause osmotic diuresis and volume depletion Baseline blood pressure in the low-normal range (systolic 90-110 mmHg) Advanced age (65 years and older) Autonomic dysfunction or diabetic neuropathy Rapid or substantial weight loss Inadequate fluid intake or gastrointestinal side effects causing dehydration Concomitant use of other medications that lower blood pressure Patients with type 1 diabetes using off-label GLP-1 therapy or those with longstanding type 2 diabetes and cardiovascular autonomic neuropathy may be at higher risk for orthostatic hypotension
Researchers are examining its impact on the somatotropic axis to better understand its effects on growth, recovery, and metabolism
Distinct roles of RIP1RIP3 hetero- and RIP3RIP3 homo-interaction in mediating necroptosis
However, the exposure to BPC-157 appeared to significantly reduce plasma extravasation, histological alterations potentially associated with inflammation, and alveolar bone resorption
